Skip to main content
14 August 2026
03 February 2026

SanegeneBio, Genentech Partner on RNAi Therapeutics Development

SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced a global licensing agreement with Genentech, a member of the Roche Group, to advance one of its RNAi programs based on its proprietary RNAi platform. Under the agreement, SanegeneBio grants Genentech exclusive worldw…

02 February 2026

SomaLogic Acquisition Advances Illumina’s Drug Discovery Push

Illumina, Inc. announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and posit…

29 January 2026

WuXi Biologics, Sinorda Partner on Bispecific Antibody for IBD

WuXi Biologics , a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IB…

28 January 2026

Siegfried to acquire high-quality small molecules drug substance capacity in the US

Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience. The acquired businesses include three high…

27 January 2026

Hetero Enters Algeria Through Strategic Biosimilars Partnership with MS Pharma

MS Pharma Group, a leading regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.  The exclusive agreement…

23 January 2026

Thermo Fisher and NVIDIA Partner to Scale AI-Powered Lab Automation

Thermo Fisher Scientific Inc., the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase …

22 January 2026

BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market

BD, a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate® 5.5 a…

21 January 2026

Syngene and Bristol Myers Squibb Broaden Integrated Drug Development Collaboration

Syngene International, a global contract research, development, and manufacturing organization, announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning di…

21 January 2026

Insilico and Hygtia Collaborate on AI-Discovered NLRP3 Inhibitor for CNS Disorders

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), announced a co-development collaboration agreement for Insilico's ISM8969 program. Through the partnership, the two parties aim to accelerate the globa…

Page 18 of 37